Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 97 articles:
HTML format



Single Articles


    November 2021
  1. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
    PubMed    


    October 2021

  2. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.
    PubMed    


  3. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    PubMed     Abstract available


    September 2021
  4. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
    PubMed    


    August 2021
  5. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available


  6. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    PubMed     Abstract available


  7. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    PubMed     Abstract available


    July 2021
  8. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    PubMed     Abstract available


    June 2021
  9. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    PubMed    


  10. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
    PubMed    


    May 2021
  11. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available


  12. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed    


    April 2021
  13. YADAV DK, Singh A, Zhang Q, Bai X, et al
    Involvement of liver in COVID-19: systematic review and meta-analysis.
    Gut. 2021;70:807-809.
    PubMed    


  14. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    PubMed     Abstract available


  15. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    PubMed     Abstract available


    March 2021
  16. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.
    PubMed    


  17. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.
    PubMed    


  18. SAPENA V, Enea M, Torres F, Celsa C, et al
    Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
    Gut. 2021 Mar 19. pii: gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663.
    PubMed     Abstract available


  19. ZHAN K, Liao S, Li J, Bai Y, et al
    Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation.
    Gut. 2021;70:628-629.
    PubMed    


  20. KIM DH, Hong SB, Choi SH, Kim SY, et al
    Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323615. doi: 10.1136/gutjnl-2020-323615.
    PubMed    


  21. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    PubMed     Abstract available


    February 2021
  22. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available


  23. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    PubMed     Abstract available


  24. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.
    PubMed    


  25. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available


    January 2021
  26. YASKOLKA MEIR A, Rinott E, Tsaban G, Zelicha H, et al
    Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.
    Gut. 2021 Jan 18. pii: gutjnl-2020-323106. doi: 10.1136/gutjnl-2020-323106.
    PubMed     Abstract available


  27. AOKI S, Inoue K, Klein S, Halvorsen S, et al
    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
    Gut. 2021 Jan 11. pii: gutjnl-2020-322493. doi: 10.1136/gutjnl-2020-322493.
    PubMed     Abstract available


  28. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.
    PubMed    


  29. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    


  30. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    PubMed     Abstract available


  31. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    PubMed     Abstract available


    December 2020
  32. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available


  33. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available


  34. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    PubMed     Abstract available


    November 2020
  35. SUN N, Shen C, Zhang L, Wu X, et al
    Hepatic Kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance.
    Gut. 2020 Nov 30. pii: gutjnl-2020-321774. doi: 10.1136/gutjnl-2020-321774.
    PubMed     Abstract available


  36. CALDERARO J, Kather JN
    Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322880. doi: 10.1136/gutjnl-2020-322880.
    PubMed     Abstract available


  37. KOH EH, Yoon JE, Ko MS, Leem J, et al
    Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
    Gut. 2020 Nov 18. pii: gutjnl-2020-322509. doi: 10.1136/gutjnl-2020-322509.
    PubMed     Abstract available


  38. HAO L, Zhong W, Dong H, Guo W, et al
    ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.
    Gut. 2020 Nov 11. pii: gutjnl-2020-321548. doi: 10.1136/gutjnl-2020-321548.
    PubMed     Abstract available


  39. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    PubMed     Abstract available


  40. CUBERO FJ
    Keeping the liver fit with TREM2 during hepatic carcinogenesis.
    Gut. 2020 Nov 4. pii: gutjnl-2020-322638. doi: 10.1136/gutjnl-2020-322638.
    PubMed    


  41. SHANG R, Song X, Wang P, Zhou Y, et al
    Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Gut. 2020 Nov 3. pii: gutjnl-2020-320716. doi: 10.1136/gutjnl-2020-320716.
    PubMed     Abstract available


  42. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.
    PubMed    


    October 2020
  43. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    PubMed     Abstract available


  44. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.
    PubMed    


  45. TILG H, Targher G
    NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought.
    Gut. 2020 Oct 19. pii: gutjnl-2020-323188. doi: 10.1136/gutjnl-2020-323188.
    PubMed    


  46. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available


  47. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available


  48. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.
    PubMed    


  49. ZHANG N, Jiang W, Zhang Y, Song TQ, et al
    Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria.
    Gut. 2020;69:1893-1895.
    PubMed    


  50. DE TONI EN
    Immune checkpoint inhibitors: use them early, combined and instead of TACE?
    Gut. 2020;69:1887-1888.
    PubMed    


  51. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    PubMed     Abstract available


  52. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    PubMed     Abstract available


    September 2020
  53. SHI JY, Wang X, Ding GY, Dong Z, et al
    Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.
    Gut. 2020 Sep 30. pii: gutjnl-2020-320930. doi: 10.1136/gutjnl-2020-320930.
    PubMed     Abstract available


  54. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available


  55. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available


  56. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.
    PubMed    


  57. VON FELDEN J, Garcia-Lezana T, Schulze K, Losic B, et al
    Liquid biopsy in the clinical management of hepatocellular carcinoma.
    Gut. 2020 Sep 3. pii: gutjnl-2019-320282. doi: 10.1136/gutjnl-2019-320282.
    PubMed     Abstract available


  58. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    PubMed     Abstract available


  59. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.
    PubMed    


    August 2020
  60. SHARMA S, Elhence A, Vaishnav M, Kumar R, et al
    COVID-19 in patients with cirrhosis: understanding adverse impact.
    Gut. 2020 Aug 21. pii: gutjnl-2020-322561. doi: 10.1136/gutjnl-2020-322561.
    PubMed    


  61. YAMAMOTO A, Kawada N, Jogo A, Murai K, et al
    Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322367. doi: 10.1136/gutjnl-2020-322367.
    PubMed    


  62. YANG H, Sun L, Mao Y
    Response letter to: letter to the editor: three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Aug 14. pii: gutjnl-2020-322471. doi: 10.1136/gutjnl-2020-322471.
    PubMed    


  63. PINTER M, Scheiner B, Peck-Radosavljevic M
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Gut. 2020 Aug 3. pii: gutjnl-2020-321702. doi: 10.1136/gutjnl-2020-321702.
    PubMed     Abstract available


  64. BOLLIPO S, Kapuria D, Rabiee A, Ben-Yakov G, et al
    One world, one pandemic, many guidelines: management of liver diseases during COVID-19.
    Gut. 2020;69:1369-1372.
    PubMed    


  65. TARGHER G, Mantovani A, Byrne CD, Wang XB, et al
    Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
    Gut. 2020;69:1545-1547.
    PubMed    


  66. RADU P, Dufour JF
    Changing TACTICS in intermediate HCC: TACE plus sorafenib.
    Gut. 2020;69:1374-1376.
    PubMed    


  67. TILG H, Burcelin R, Tremaroli V
    Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?
    Gut. 2020;69:1373-1374.
    PubMed    


  68. JOHNSTON M, Cook C, Buchanan RM
    RE: Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2020;69:1536-1537.
    PubMed    


    July 2020
  69. KAUR S, Tripathi DM, Ghosh S
    Three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Jul 21. pii: gutjnl-2020-322317. doi: 10.1136/gutjnl-2020-322317.
    PubMed    


  70. BAJAJ JS, Garcia-Tsao G, Biggins S, Kamath PS, et al
    Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
    Gut. 2020 Jul 13. pii: gutjnl-2020-322118. doi: 10.1136/gutjnl-2020-322118.
    PubMed     Abstract available


  71. WEBER S, Mayerle J, Irlbeck M, Gerbes AL, et al
    Severe liver failure during SARS-CoV-2 infection.
    Gut. 2020;69:1365-1367.
    PubMed    


  72. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.
    PubMed    


    June 2020
  73. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.
    PubMed    


  74. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    PubMed     Abstract available


  75. STENGEL S, Steube A, Kose-Vogel N, Kirchberger-Tolstik T, et al
    Primed circulating monocytes are a source of IL-1beta in patients with cirrhosis and ascites.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321597. doi: 10.1136/gutjnl-2020-321597.
    PubMed    


  76. BECCHETTI C, Zambelli MF, Pasulo L, Donato MF, et al
    COVID-19 in an international European liver transplant recipient cohort.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321923. doi: 10.1136/gutjnl-2020-321923.
    PubMed     Abstract available


  77. BREITKOPF-HEINLEIN K, Syn WK
    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.
    PubMed    


  78. BAYARD Q, Nault JC, Zucman-Rossi J
    RSPO2 abnormal transcripts result from read-through in liver tumours with high ss-catenin activation and CTNNB1 mutations.
    Gut. 2020;69:1152-1153.
    PubMed    


  79. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available


  80. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available


    May 2020
  81. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    PubMed    


  82. YANG H, Sun L, Pang Y, Hu D, et al
    Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure.
    Gut. 2020 May 20. pii: gutjnl-2019-319960. doi: 10.1136/gutjnl-2019-319960.
    PubMed     Abstract available


  83. NATHANI P, Gopal P, Rich N, Yopp A, et al
    Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis.
    Gut. 2020 May 12. pii: gutjnl-2020-321040. doi: 10.1136/gutjnl-2020-321040.
    PubMed     Abstract available


  84. DUFOUR JF, Caussy C, Loomba R
    Combination for therapy non-alcoholic steatohepatitis: rationale, opportunities and challenges.
    Gut. 2020 May 7. pii: gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.
    PubMed     Abstract available


    April 2020
  85. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    PubMed    


  86. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    PubMed     Abstract available


  87. CINNAMON E, Pikarsky E
    Are we ready for targeted therapy combinations in HCC?
    Gut. 2020;69:613-614.
    PubMed    


  88. AVILA MA, Dufour JF, Gerbes AL, Zoulim F, et al
    Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.
    Gut. 2020;69:764-780.
    PubMed     Abstract available


  89. LA BELLA T, Imbeaud S, Peneau C, Mami I, et al
    Adeno-associated virus in the liver: natural history and consequences in tumour development.
    Gut. 2020;69:737-747.
    PubMed     Abstract available


  90. NATHWANI R, Mullish BH, Kockerling D, Rajani N, et al
    Recurrent bacteraemia following variceal haemorrhage.
    Gut. 2020;69:726-780.
    PubMed    


    March 2020
  91. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available


  92. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available


  93. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available


  94. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    PubMed    


    February 2020
  95. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available


    January 2020
  96. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available


    December 2019
  97. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: